Cargando…

Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth

BACKGROUND: Although there are reports that metronomic cyclophosphamide (CTX) can be immune stimulating, the impact of its combination with anti-CTLA-4 immunotherapy for the treatment of cancer remains to be evaluated. METHODS: Murine EMT-6/P breast cancer, or its cisplatin or CTX-resistant variants...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parra, Karla, Valenzuela, Paloma, Lerma, Natzidielly, Gallegos, Alejandra, Reza, Luis C, Rodriguez, Georgialina, Emmenegger, Urban, Di Desidero, Teresa, Bocci, Guido, Felder, Mitchell S, Manciu, Marian, Kirken, Robert A, Francia, Giulio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294484/ https://www.ncbi.nlm.nih.gov/pubmed/28056464 http://dx.doi.org/10.1038/bjc.2016.429

Ejemplares similares

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
por: Orlandi, P, et al.
Publicado: (2013)

Optimization of biomarkers-based classification scores as progression-free survival predictors: an intuitive graphical representation
por: Manciu, Marian, et al.
Publicado: (2018)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review
por: Parshad, Shruti, et al.
Publicado: (2022)

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
por: Di Desidero, Teresa, et al.
Publicado: (2015)

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
por: Cham, K K Y, et al.
Publicado: (2010)

Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia
por: Frydecka, I, et al.
Publicado: (2004)

CTLA-4 blockade: therapeutic potential in cancer treatments
por: Tarhini, Ahmad A, et al.
Publicado: (2010)

Cyclic Metronomic Chemotherapy for Pediatric Tumors: Six Case Reports and a Review of the Literature
por: Carcamo, Benjamin, et al.
Publicado: (2022)

Quadruple and Truncated MEK3 Mutants Identified from Acute Lymphoblastic Leukemia Promote Degradation and Enhance Proliferation
por: Ayala-Marin, Yoshira M., et al.
Publicado: (2021)

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
por: Watanabe, Tomofumi, et al.
Publicado: (2023)

Protective Immunity to Nematode Infection Is Induced by CTLA-4 Blockade
por: McCoy, Kathy, et al.
Publicado: (1997)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

S43. Dendritic cell vaccination combined with CTLA4 blockade
por: Thielemans, K, et al.
Publicado: (2014)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

Radiotherapy enhances responses of lung cancer to CTLA-4 blockade
por: Wilkins, Anna, et al.
Publicado: (2019)

Radiotherapy induces responses of lung cancer to CTLA-4 blockade
por: Formenti, Silvia C., et al.
Publicado: (2018)

Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells
por: Lev, D C, et al.
Publicado: (2004)

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
por: Allegrini, Giacomo, et al.
Publicado: (2012)

Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells
por: Kikuchi, J, et al.
Publicado: (2008)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade
por: Loebinger, M R, et al.
Publicado: (2008)

Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
por: Wada, Satoshi, et al.
Publicado: (2013)

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
por: Camacho, Luis H
Publicado: (2015)

The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology
por: Zhang, Shashuang, et al.
Publicado: (2020)

A T cell repertoire timestamp is at the core of responsiveness to CTLA-4 blockade
por: Philip, Hagit, et al.
Publicado: (2021)

Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24–25 June 2014, Milan
por: Bouche, Gauthier, et al.
Publicado: (2014)

Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutant
por: Shimizu, Y, et al.
Publicado: (2008)

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
por: von Euw, Erika, et al.
Publicado: (2009)

Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
por: Jure-Kunkel, Maria, et al.
Publicado: (2013)

CTLA-4 checkpoint blockade in breast cancer, a case in point report
por: Dellepiane, Chiara, et al.
Publicado: (2015)

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors
por: Zappasodi, Roberta, et al.
Publicado: (2021)

Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
por: Zhou, Yifan, et al.
Publicado: (2022)

Metronomics for thymic carcinoma
por: del Toro, Jacobo Muñoz, et al.
Publicado: (2014)

Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells
por: Carbajo-Pescador, S, et al.
Publicado: (2013)

Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies
por: Banchi, Marta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j6qiccj5v4j4jl1uljs2la7n2g